Nothing Special   »   [go: up one dir, main page]

HK1080481A1 - Phosphonooxy quinazoline derivatives and their pharmaceutical use - Google Patents

Phosphonooxy quinazoline derivatives and their pharmaceutical use

Info

Publication number
HK1080481A1
HK1080481A1 HK06100400A HK06100400A HK1080481A1 HK 1080481 A1 HK1080481 A1 HK 1080481A1 HK 06100400 A HK06100400 A HK 06100400A HK 06100400 A HK06100400 A HK 06100400A HK 1080481 A1 HK1080481 A1 HK 1080481A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical use
quinazoline derivatives
phosphonooxy
phosphonooxy quinazoline
derivatives
Prior art date
Application number
HK06100400A
Other languages
English (en)
Inventor
Nicola Murdoch Heron
Frederic Henri Jung
Georges Rene Pasquet
Andrew A Mortlock
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1080481A1 publication Critical patent/HK1080481A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK06100400A 2002-12-24 2006-01-10 Phosphonooxy quinazoline derivatives and their pharmaceutical use HK1080481A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02293238 2002-12-24
EP03291315 2003-06-02

Publications (1)

Publication Number Publication Date
HK1080481A1 true HK1080481A1 (en) 2006-04-28

Family

ID=32683824

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06100400A HK1080481A1 (en) 2002-12-24 2006-01-10 Phosphonooxy quinazoline derivatives and their pharmaceutical use
HK08102177.3A HK1111417A1 (en) 2002-12-24 2008-02-27 Quinazoline derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK08102177.3A HK1111417A1 (en) 2002-12-24 2008-02-27 Quinazoline derivatives

Country Status (30)

Country Link
US (4) US7528121B2 (xx)
EP (2) EP1847539B1 (xx)
JP (3) JP4422102B2 (xx)
KR (1) KR101010299B1 (xx)
AR (2) AR042668A1 (xx)
AT (2) ATE370958T1 (xx)
AU (1) AU2003290313B2 (xx)
BR (1) BRPI0317717B8 (xx)
CA (1) CA2511613C (xx)
CL (1) CL2003002731A1 (xx)
CY (2) CY1107775T1 (xx)
DE (2) DE60328735D1 (xx)
DK (2) DK1847539T3 (xx)
ES (2) ES2329623T3 (xx)
HK (2) HK1080481A1 (xx)
IL (2) IL169112A (xx)
IS (2) IS2504B (xx)
MX (1) MXPA05006918A (xx)
MY (2) MY136174A (xx)
NO (2) NO335193B1 (xx)
NZ (1) NZ540698A (xx)
PL (2) PL223998B1 (xx)
PT (2) PT1847539E (xx)
RU (3) RU2357971C2 (xx)
SA (1) SA04240504B1 (xx)
SI (2) SI1578755T1 (xx)
TW (2) TWI336327B (xx)
UA (1) UA83814C2 (xx)
UY (1) UY28149A1 (xx)
WO (1) WO2004058781A1 (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100491372C (zh) * 2001-12-24 2009-05-27 阿斯特拉曾尼卡有限公司 作为欧若拉激酶抑制剂的取代喹唑啉衍生物
CA2508921A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
RU2357971C2 (ru) 2002-12-24 2009-06-10 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
CN1809557B (zh) * 2003-04-16 2012-07-04 阿斯利康(瑞典)有限公司 化合物
EP2251343A1 (en) * 2003-05-15 2010-11-17 Arqule, Inc. Imidazothiazoles as p38-kinase-inhibitors
WO2004105764A1 (en) * 2003-06-02 2004-12-09 Astrazeneca Ab (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
CN101072758B (zh) * 2004-10-12 2013-07-31 阿斯利康(瑞典)有限公司 喹唑啉衍生物
WO2006040526A1 (en) * 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives for use against cancer
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006044869A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
GB0609617D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GB0609621D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
WO2009111028A1 (en) * 2008-03-04 2009-09-11 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
JP5502072B2 (ja) 2008-04-30 2014-05-28 ナショナル ヘルス リサーチ インスティテューツ オーロラキナーゼ阻害剤としての縮合二環式ピリミジン化合物
AU2009267161B2 (en) * 2008-07-03 2014-11-06 Merck Patent Gmbh Naphthyridininones as Aurora kinase inhibitors
AU2009322158A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. RAF inhibitors and their uses
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
CA2746652C (en) 2008-12-11 2018-03-06 Axcentua Pharmaceuticals Ab Crystalline forms of genistein
CN102264368B (zh) 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
ES2609578T3 (es) 2011-03-04 2017-04-21 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CA2900652C (en) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
TWI630203B (zh) * 2013-02-21 2018-07-21 葛蘭素史克智慧財產發展有限公司 做為激酶抑制劑的喹唑啉類
SI3311845T1 (sl) * 2013-09-16 2020-06-30 Astrazeneca Ab Terapevtski polimerni nanodelci in postopki njihove izdelave in uporabe
EP3062618B1 (en) 2013-11-01 2020-02-05 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
SG11202001728YA (en) 2017-09-08 2020-03-30 Univ Leland Stanford Junior Enpp1 inhibitors and their use for the treatment of cancer
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en) 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
WO1995033724A1 (en) 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (xx) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR100459052B1 (ko) 1995-12-18 2005-01-15 서젠, 인크. Aur-1및(또는)aur-2관련질병의진단및치료
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
CA2244897C (en) 1996-03-05 2006-04-11 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
JP2002527436A (ja) 1998-10-08 2002-08-27 アストラゼネカ アクチボラグ キナゾリン誘導体
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CA2384291A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
US6919338B2 (en) 2000-06-28 2005-07-19 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
CA2411160A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
CN100491372C (zh) * 2001-12-24 2009-05-27 阿斯特拉曾尼卡有限公司 作为欧若拉激酶抑制剂的取代喹唑啉衍生物
RU2357971C2 (ru) * 2002-12-24 2009-06-10 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
CA2508921A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
CN1809557B (zh) * 2003-04-16 2012-07-04 阿斯利康(瑞典)有限公司 化合物

Also Published As

Publication number Publication date
CY1107775T1 (el) 2013-06-19
SI1578755T1 (sl) 2007-12-31
HK1111417A1 (en) 2008-08-08
IL185176A (en) 2011-10-31
DE60315892T2 (de) 2008-08-14
JP2006512418A (ja) 2006-04-13
IL169112A (en) 2010-12-30
US9018191B2 (en) 2015-04-28
NO335446B1 (no) 2014-12-15
UY28149A1 (es) 2004-07-30
BRPI0317717B8 (pt) 2021-05-25
IS8714A (is) 2008-02-13
US20150307534A1 (en) 2015-10-29
NO335193B1 (no) 2014-10-20
JP4503090B2 (ja) 2010-07-14
IS2504B (is) 2009-04-15
EP1847539B1 (en) 2009-08-05
NO20052855D0 (no) 2005-06-13
KR101010299B1 (ko) 2011-01-25
DE60328735D1 (de) 2009-09-17
EP1578755B1 (en) 2007-08-22
EP1578755A1 (en) 2005-09-28
PT1578755E (pt) 2007-10-19
ES2290529T3 (es) 2008-02-16
SI1847539T1 (sl) 2010-01-29
US20060116357A1 (en) 2006-06-01
PT1847539E (pt) 2009-10-06
MY136174A (en) 2008-08-29
AU2003290313B2 (en) 2007-05-10
BR0317717A (pt) 2005-11-22
TWI393710B (zh) 2013-04-21
BRPI0317717B1 (pt) 2017-12-19
ATE370958T1 (de) 2007-09-15
WO2004058781A1 (en) 2004-07-15
PL223998B1 (pl) 2016-11-30
CY1109479T1 (el) 2014-08-13
ES2329623T3 (es) 2009-11-27
IL169112A0 (en) 2009-02-11
RU2350611C1 (ru) 2009-03-27
JP2009046514A (ja) 2009-03-05
EP1847539A1 (en) 2007-10-24
PL377680A1 (pl) 2006-02-06
TW200510342A (en) 2005-03-16
DK1578755T3 (da) 2007-11-12
JP4906608B2 (ja) 2012-03-28
UA83814C2 (ru) 2008-08-26
TW201102369A (en) 2011-01-16
RU2007121850A (ru) 2008-12-20
US20140162984A1 (en) 2014-06-12
JP4422102B2 (ja) 2010-02-24
US8268841B2 (en) 2012-09-18
NO20131444L (no) 2005-08-03
CA2511613C (en) 2012-10-02
NZ540698A (en) 2008-05-30
IS7948A (is) 2005-07-20
MY147761A (en) 2013-01-31
US20100069412A1 (en) 2010-03-18
PL412704A1 (pl) 2015-10-12
PL221490B1 (pl) 2016-04-29
SA04240504A (ar) 2005-12-03
IL185176A0 (en) 2007-12-03
KR20050088333A (ko) 2005-09-05
JP2007326862A (ja) 2007-12-20
MXPA05006918A (es) 2005-08-18
TWI336327B (en) 2011-01-21
ATE438644T1 (de) 2009-08-15
US9567358B2 (en) 2017-02-14
SA04240504B1 (ar) 2008-04-01
DK1847539T3 (da) 2009-11-09
AR042668A1 (es) 2005-06-29
AR057753A2 (es) 2007-12-19
RU2357971C2 (ru) 2009-06-10
AU2003290313A1 (en) 2004-07-22
IS2884B (is) 2014-06-15
US7528121B2 (en) 2009-05-05
CA2511613A1 (en) 2004-07-15
CL2003002731A1 (es) 2005-01-07
DE60315892D1 (de) 2007-10-04
NO20052855L (no) 2005-08-03
RU2005123485A (ru) 2006-03-10

Similar Documents

Publication Publication Date Title
HK1080481A1 (en) Phosphonooxy quinazoline derivatives and their pharmaceutical use
IL170758A0 (en) 7-amino-isoindolyl compounds and their pharmaceutical uses
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
HK1084883A1 (en) 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof
GB0215823D0 (en) Quinazoline derivatives
IL183583A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
HK1091199A1 (en) Quinazoline derivatives and use thereof in the manufacture of medicaments
EP1479666A4 (en) ESTER CONNECTION AND THEIR MEDICAL USE
IL165986A0 (en) Isoquinoline and quinazoline derivatives and pharmaceutical compositions containing the same
AU2003235956A1 (en) Quinazoline derivative and medicine
AU2002950853A0 (en) Aminopyrimidine compound and pharmaceutical use thereof
IL149377A0 (en) Pharmaceutical formulation comprising melatonin
GB0207410D0 (en) Compounds and their therapeutic use
IL172087A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
EP1541174A4 (en) MEDICINE OR COSMETIC PRODUCT
GB0206505D0 (en) Pharmaceutical combination
ZA200504997B (en) Phosphonooxy quinazolin derivatives and their pharmaceutical use
PL374817A1 (en) Quinazoline derivatives
PL373409A1 (en) Pharmaceutical combination
AU2003264474A8 (en) Novel uracil derivatives and medicinal use thereof
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use
EP1499338A4 (en) 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSENES-17-ONE AND 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTAN-17-ONE AND THEIR DERIVATIVES
AU2003238900A8 (en) Pharmaceutical formulation
GB0328255D0 (en) Quinazoline derivatives and their uses
GB0220451D0 (en) Pharmaceutical use

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20231225